doi: 10.1007/BF01647753.
Bacteriological effects of anti-Pseudomonas aeruginosa chemotherapy in cystic fibrosis
Affiliations
- PMID: 3121519
- DOI: 10.1007/BF01647753
Item in Clipboard
Bacteriological effects of anti-Pseudomonas aeruginosa chemotherapy in cystic fibrosis
Infection.
1987.
Abstract
Strains of Pseudomonas aeruginosa resistant to clinically relevant antibiotics (beta-lactams, quinolones, aminoglycosides) were detectable in sputa of cystic fibrosis patients. Correlations between in vitro susceptibility and bacteriological results in vivo were demonstrated at a quantitative level. P. aeruginosa strains susceptible prior to antibiotic therapy were observed to become resistant towards each of the compounds used for treatment. We conclude that antibiotic therapy in cystic fibrosis has to be optimized by culture specific selection of the drugs and consecutive bacteriological follow-ups.
Similar articles
-
Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa.Antimicrob Agents Chemother. 1995 Nov;39(11):2411-4. doi: 10.1128/AAC.39.11.2411. Antimicrob Agents Chemother. 1995. PMID: 8585718 Free PMC article.
-
Penicillin-binding protein 3 is a common adaptive target among Pseudomonas aeruginosa isolates from adult cystic fibrosis patients treated with β-lactams.Int J Antimicrob Agents. 2019 May;53(5):620-628. doi: 10.1016/j.ijantimicag.2019.01.009. Epub 2019 Jan 19. Int J Antimicrob Agents. 2019. PMID: 30664925
-
Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.J Clin Pharm Ther. 2018 Dec;43(6):836-843. doi: 10.1111/jcpt.12722. Epub 2018 Jun 29. J Clin Pharm Ther. 2018. PMID: 29959786
-
Rational parameters for antibiotic therapy in patients with cystic fibrosis.Infection. 1987 Jul-Aug;15(4):300-7. doi: 10.1007/BF01644142. Infection. 1987. PMID: 3117704 Review.
-
Antimicrobials in cystic fibrosis: emergence of resistance and implications for treatment.Semin Respir Infect. 1992 Sep;7(3):210-7. Semin Respir Infect. 1992. PMID: 1475544 Review.
Cited by
-
Pulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers.Int Arch Med. 2008 Nov 7;1(1):24. doi: 10.1186/1755-7682-1-24. Int Arch Med. 2008. PMID: 18992146 Free PMC article.
-
Selective pressure of antistaphylococcal chemotherapeutics in favour of Pseudomonas aeruginosa in cystic fibrosis.Infection. 1987 Nov-Dec;15(6):469-70. doi: 10.1007/BF01647240. Infection. 1987. PMID: 3125114
-
Correlation between activity of beta-lactam agents in vitro and bacteriological outcome in acute pulmonary exacerbations of cystic fibrosis.Eur J Clin Microbiol Infect Dis. 1995 Apr;14(4):291-6. doi: 10.1007/BF02116521. Eur J Clin Microbiol Infect Dis. 1995. PMID: 7649191 Clinical Trial.
-
Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis.Thorax. 2004 Nov;59(11):955-9. doi: 10.1136/thx.2003.017707. Thorax. 2004. PMID: 15516471 Free PMC article.